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Anumber of guanidino-substituted analogues of L-arginine are synthesized endogenously and can act
as inhibitors of nitric oxide synthase, the enzyme
responsible for the formation of nitric oxide (NO) from
the amino acid precursor L-arginine.1,2 Of particular
interest are NG,NG-dimethyl L-arginine (ADMA) and
NG-monomethyl L-arginine (L-NMMA). The plasma
levels of both of these L-arginine analogues are signifi-
cantly increased in various pathologic conditions,
including end-stage renal failure,3 congestive heart fail-
ure,4 pre-eclampsia,5 peripheral arterial occlusive dis-
ease,6 and hypertension.7,8 Furthermore, these com-
pounds produced dose-dependent inhibition of nitrite
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production by macrophages (J774 cells) and reversed
endothelium-dependent relaxation in human saphenous
veins9 and human and rat cerebral arteries.10,11
Whether these compounds affect the responsiveness
of arterial grafts used for coronary bypass surgery, such
as the internal thoracic and radial arteries, remains to be
determined. An increase in plasma concentrations of
these compounds is likely to induce a decreased syn-
thesis of endothelial NO and a diminished response to
endothelium-mediated relaxation. Both circumstances
may explain, at least in part, the differences in long-
term survival and reactivity to pharmacologic agents
between these arteries.12 The purpose of the present
work was to evaluate the potency and selectivity of
ADMA, L-NMMA, methylguanidine (MG), and
aminoguanidine (AG) on endothelium-dependent and
endothelium-independent relaxation of human internal
thoracic and radial arteries. Because continuous release
of NO from endothelial cells is an important determi-
nant of the underlying smooth muscle tone in animals
and human subjects,13-17 we also examined the ability
of these compounds to inhibit basal NO release by
measuring the effect on vascular tone.
Methods
Internal thoracic and radial arteries were obtained from 16
multiorgan donors during procurement of organs for trans-
plantation (10 men and 6 women; age range, 17-60 years).
The study was approved by the ethical committee of our insti-
tution. The vessels were immediately placed in cold (4°C)
modified Krebs solution (for composition see below) aerated
with 95% oxygen and 5% carbon dioxide until use (within 8
hours of collection).
The vessels were cleaned of adherent connective tissue and
cut into rings (3 mm in length) under a dissecting microscope
(Leica Geosystems, Heerbrugg, Switzerland). In approxi-
mately 30% of the artery rings, the endothelium was removed
mechanically by inserting a roughened stainless-steel wire
into the lumen and gently rolling the vessel ring on wet filter
paper. Each ring was suspended between two stainless-steel
L-shaped pins in 4-mL organ baths containing modified
Krebs solution of the following composition: NaCl, 115
mmol/L; KCl, 4.6 mmol/L; MgSO4, 1.2 mmol/L; CaCl2, 2.5
mmol/L; NaHCO3, 25 mmol/L; KH2PO4, 1.2 mmol/L; glu-
cose, 11.1 mmol/L; and disodium ethylenediamine tetraacetic
acid, 0.01 mmol/L. The solution was equilibrated with 95%
oxygen and 5% carbon dioxide to give a pH of 7.3 to 7.4.
Temperature was held at 37°C. One pin was fixed to the organ
bath wall, and the other was connected to a strain gauge
(model FT03; Grass Instrument Division of Astro-Med, Inc,
West Warwick, RI). Changes in isometric force were record-
ed on a Macintosh computer (Apple Computer, Cupertino,
Calif) by use of Chart version 3.4/s software and a
MacLab/8e data acquisition system (ADInstruments,
Mountain View, Calif). To establish the resting tension for
maximal force development, we performed a series of pre-
liminary experiments on rings of similar length and outer
diameter, which were exposed repeatedly to 100 mmol/L
KCl. Basal tension was increased gradually until contractions
were maximal. The optimal resting tension was 3g for the
internal thoracic artery and 4g for the radial artery. The rings
were allowed to attain a steady level of tension during a 2- to
3-hour accommodation period before testing. Functional
integrity of the endothelium was confirmed routinely by the
presence of relaxation induced by acetylcholine (10–8 to 10–7
mol/L) during contraction obtained with norepinephrine
(10–7 to 3×10–7 mol/L).
All experiments were performed in the presence of 10–5
mol/L indomethacin (INN: indometacin) to inhibit prostanoid
synthesis.
To study contraction, concentration-response curves to L-
NMMA (10–6 to 10–3 mol/L), ADMA (10–6 to 10–3 mol/L),
AG (10–5 to 3×10–3 mol/L), and MG (10–5 to 3×10–3 mol/L)
were determined in artery rings under resting tension. In
another series of experiments concentration-response curves
were determined after evoking tone (approximately 500 mg
for the internal thoracic artery and 700 mg for the radial
artery) with norepinephrine. In a separate group of experi-
ments, the contractile effects of guanidino compounds were
studied in the presence of L-arginine (10–3 mol/L).
To study the effects of guanidino compounds on relaxation,
vessels were precontracted with norepinephrine (1.5-2 g for
the internal thoracic artery and 3-4 g for the radial artery),
and cumulative relaxation curves to either acetylcholine
(10–10 to 10–5 mol/L) or sodium nitroprusside (10–10 to 10–7
mol/L) were constructed in the absence and presence of L-
NMMA, ADMA, AG, or MG (all at 10–5 to 10–3 mol/L). In a
separate series of experiments, the effects of guanidino com-
pounds on acetylcholine-induced relaxation were studied in
the presence of L-arginine (10–3 mol/L).
Drugs. The following drugs were used: acetylcholine chlo-
ride, norepinephrine hydrochloride, NG-monomethyl L-argi-
nine acetate, NG,NG-dimethylarginine hydrochloride,
aminoguanidine hydrochloride, methylguanidine hydrochlo-
ride, L-arginine hydrochloride, indomethacin, and sodium
nitroprusside dihydrate (Sigma Chemical Co, St Louis, Mo).
Drugs were prepared and diluted in distilled water, except for
indomethacin, which was dissolved in absolute ethanol and
sodium bicarbonate solution (150 mmol/L), and readjusted to
pH 7.4 with HCl before use. Stock solutions of the drugs
were freshly prepared every day.
Data analysis. All values are expressed as means ± SEM.
The contractile effects of L-NMMA, ADMA, AG, and MG were
determined after evoking submaximal tone with norepinephrine
(3 × 10–8 to 10–7 mol/L). The change from the preexisting ten-
sion was expressed as a percentage of the response to KCl (100
mmol/L). Relaxation was expressed as a percentage of the nor-
epinephrine-induced contraction (3 × 10–7 mol/L).
Concentrations of agonist producing half-maximal contrac-
tion or relaxation (EC50) were determined from individual
concentration-response curves by using nonlinear regression
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analysis, and from these values, the geometric means were
calculated. The number of rings taken from each subject var-
ied from 8 to 12. The responses obtained in each subject were
averaged to yield a single value. Therefore, all (n) values are
presented as the number of subjects. Differences between
agonist- and antagonist-treated groups were assessed by 2-
way analysis of variance.
Results
Maximal contractions to KCl and norepinephrine
were greater in the radial artery (9835 ± 364 and
11763 ± 1466 mg, respectively; n = 6) than in the
internal thoracic artery (4438 ± 203 and 4008 ± 567
mg, respectively; n = 5). EC50 values for norepineph-
rine were 9.3 × 10–7 mol/L in the radial artery and 
3.0 × 10–7 mol/L in the internal thoracic artery.
Arteries exposed to L-NMMA, ADMA, AG, and MG
(10–5 to 10–3 mol/L) did not show significant changes
in resting tension. In the presence of threshold concen-
trations of norepinephrine, L-NMMA and ADMA (10–6
to 10–3 mol/L) produced concentration-dependent
increases in tension in artery rings with endothelium
but not in endothelium-denuded rings (Fig 1). The EC50
values for L-NMMA and ADMA in the internal tho-
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Fig 1.  Contractions induced by L-NMMA (n = 6) and ADMA (n = 6) on rings of human internal thoracic and radi-
al arteries with and without endothelium and in rings with endothelium treated with L-arginine (10–3 mol/L, n = 4).
Contractions were determined after evoking submaximal tone with norepinephrine, and the change from the pre-
existing tone is expressed as a percentage of response to 100 mmol/L KCl. Values are means ± SEM.
racic artery were 1.4×10–5 mol/L and 6.5×10–5 mol/L,
respectively (n = 6), and 2.7×10–5 mol/L and 1.0 × 10–5
mol/L, respectively, in the radial artery (n = 6). AG and
MG augmented norepinephrine-induced tone at con-
centrations greater than 10–4 mol/L; this response was
endothelium independent (Fig 2). The EC50 values
were not determined for MG and AG because their
curves did not reach a plateau at concentrations up to 3
× 10–3 mol/L (n = 5 for each compound). Previous addi-
tion of L-arginine (10–3 mol/L) prevented the increase
in tension induced by L-NMMA (n = 4) and ADMA (n
= 4; Fig 1) but did not change contractions induced by
AG (n = 4) and MG (n = 4; Fig 2).
Acetylcholine (10–10 to 10–5 mol/L) caused endothe-
lium-dependent relaxations (EC50 = 1.7 × 10–7 mol/L
in internal thoracic artery; EC50 = 1.8 × 10–9 mol/L in
radial artery) in rings contracted with norepinephrine
(Fig 3). The relaxation induced by acetylcholine was
inhibited in a concentration-dependent manner by L-
NMMA (10–5 to 10–3 mol/L) and ADMA (10–5 to 10–3
mol/L; Fig 3). Maximal relaxations of internal thoracic
arteries evoked by acetylcholine in the presence of L-
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Fig 2.  Contractions induced by AG (n = 5) and MG (n = 5) on rings of human internal thoracic and radial arteries
with and without endothelium and in rings with endothelium treated with L-arginine (10–3 mol/L, n = 4). Values are
means ± SEM.
NMMA (10–3 mol/L, n = 5) and ADMA (10–3 mol/L,
n = 5) were 10.6% ± 7.0% and 18.0% ± 11.8%, respec-
tively. However, a sizeable relaxation of the radial
arteries to acetylcholine remained in the presence of
the highest concentration of L-NMMA or ADMA
(78.5% ± 7.1% and 79.5% ± 10.0%, respectively; 
Fig 3). The inhibitory effects of L-NMMA and ADMA
on acetylcholine-induced relaxation were completely
prevented by L-arginine (10–3 mol/L) in both arteries.
Neither MG (10–5 to 10–3 mol/L, n = 4) nor AG (10–5
to 10–3 mol/L, n = 4) had any effect on the relaxation
induced by acetylcholine (results not shown).
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Fig 3.  Inhibition by L-NMMA and ADMA of the relaxation of human internal thoracic and radial artery rings
induced by acetylcholine. The inhibitory effects of L-NMMA (10–3 mol/L, n = 5) and ADMA (10–3 mol/L, n = 5)
were completely prevented in the presence of 10–3 mol/L L-arginine (n = 4). Relaxation is expressed as a percent-
age of the contraction in response to 3 × 10–7 mol/L norepinephrine. Values are means ± SEM.
In endothelium-intact and endothelium-denuded
rings, sodium nitroprusside (10–10 to 10–7 mol/L)
induced complete (100%) relaxation of precontracted
artery rings, with an EC50 of 1.0 × 10–8 mol/L for inter-
nal thoracic arteries and 5.2 × 10–9 mol/L for radial
arteries. None of the guanidino compounds (10–4
mol/L) modified the relaxation curves to sodium nitro-
prusside (n = 4 for each compound; results not shown).
Comment
The present study was designed to test the influence
of various guanidino compounds on vascular tone and
NO-dependent vasodilating function in human radial
and internal thoracic arteries. The results demonstrate
that L-NMMA and ADMA caused concentration-depen-
dent contractions of these arteries. The contractile
effects were endothelium dependent and were fully
reversed by L-arginine, the substrate for the enzyme for
NO synthesis. These findings indicate that L-NMMA
and ADMA increase the tone of these vessels by inhibit-
ing the basal release of NO from the endothelium. In
addition, the magnitude of the contractile effects sug-
gests that the internal thoracic artery releases more NO
under basal conditions than the radial artery. This dif-
ference may be of clinical relevance because it is the
basal release of NO that modifies the underlying smooth
muscle tone.13,14,18 The small contraction obtained in
the radial artery indicates a small tonic release of NO
under basal conditions. This effect is similar to that
reported in human subjects at the level of the distal seg-
ment of the epicardial coronary artery19 and is in con-
trast with a previous study in human subjects in which
L-NMMA decreased radial blood flow but did not affect
the diameter of the radial artery.20 This discrepancy with
our results may be only apparent. Apart from differ-
ences between in vivo and in vitro experiments, the con-
centrations of L-NMMA used in our experiments to
induce measurable contractile effects were higher than
those used in vivo.20 Even at high concentrations (10–4
mol/L), L-NMMA and ADMA caused only moderate
contractions of the radial artery (approximately 8% of
the maximal contraction to KCl).
AG and MG produced endothelium-independent con-
tractions and only at high concentrations. L-Arginine
did not inhibit these contractions, thus indicating that
this effect was not a consequence of inhibition of NO
synthesis but rather caused by nonspecific interaction
with the vascular smooth muscle. This finding is not
unexpected because MG is structurally similar to AG, a
compound reported to have a weak inhibitory effect on
NO production by the vascular constitutive isoform of
NO synthase.9,21,22 Nonspecific contractions induced
by high concentrations of AG and MG have previously
been shown in the human saphenous vein.9
We also examined the effects of guanidino com-
pounds on the relaxation induced by acetylcholine,
which releases endothelium-derived relaxing factor,
and by sodium nitroprusside, which releases NO with-
in the smooth muscle cells. We observed that the relax-
ation induced by acetylcholine was significantly
decreased by L-NMMA and ADMA. Because the
relaxation to sodium nitroprusside, an endothelium-
independent vasodilator, was not impaired, the absence
of relaxation to acetylcholine appears to be a conse-
quence of a decreased synthesis or release of endothe-
lial NO. In contrast, AG and MG had no effect on the
relaxation induced by acetylcholine and sodium nitro-
prusside, thus suggesting that these compounds do not
affect the synthesis of endothelial NO.
In agreement with a recent report,23 our experiments
show that the relaxant response to acetylcholine of the
internal thoracic artery was suppressed by L-NMMA or
ADMA, whereas in the radial artery the relaxation was
reduced but not abolished. This indicates that the relax-
ation in the internal thoracic artery is wholly dependent
on NO release, whereas in the radial artery factors
other than NO or prostanoids contribute to acetyl-
choline-induced relaxation. This is probably the reason
for the greater relaxant effects (in terms of EC50 values)
of acetylcholine in radial arteries than in internal tho-
racic arteries. The remaining relaxation after treatment
with NO synthase inhibitors observed in our experi-
ments in radial arteries may result from the action of
acetylcholine on endothelium-derived hyperpolarizing
factor.23-27 Although the identity of this non-NO, non-
prostanoid, endothelium-derived hyperpolarizing fac-
tor remains unknown, several studies have shown that
this factor causes hyperpolarization that has been
attributed to an increase in K+ conductance of the
smooth muscle cell membrane.24,28,29
Human subjects possess endogenous analogues of L-
arginine, especially ADMA and L-NMMA, and the
enzyme responsible for their synthesis is present in sev-
eral tissues.30 Plasma concentrations of ADMA in
healthy human subjects range from 0.5 to 1×10–6
mol/L,3,31,32 and in uremic patients they range from 1.0
to 8.7×10–6 mol/L.3,31 Concentrations of L-NMMA in
healthy control subjects appear to be 10 times lower
than those of ADMA3,32 but are increased significantly
(1.4 × 10–5 mol/L) in uremic patients.32 The increased
plasma levels of guanidino compounds associated with
a defect in NO formation may be a risk factor to be
considered in relation to a recent report33 showing that
mortality for patients undergoing coronary bypass
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surgery with chronic renal failure is higher than for
patients with normal renal function. Circulating con-
centrations of ADMA are increased in hypercholes-
terolemic subjects, thus suggesting that ADMA might
represent a novel risk factor for endothelial dysfunc-
tion.34 In fact, it has been shown that despite the
absence of angiographic evidence of atherosclerosis,
the presence of coronary risk factors may be associated
with reduced basal and stimulated release of NO from
the human coronary circulation.35 The basal release of
NO is a key factor to keep vascular smooth muscle
relaxed and to counteract the vasoconstrictor effects of
norepinephrine, angiotensin, or endothelin.
Our data indicate that inhibition of NO synthase by
accumulation of methylarginines can lead to significant
effects on arterial grafts used in coronary bypass
surgery. An increase in ADMA and L-NMMA is likely
to represent a diminished release or effect of NO, and
consequently, a decrease of blood supply to the heart is
highly conceivable. Impairment of NO formation in the
vessel wall will predispose to vasoconstriction and
favor platelet adhesion and aggregation, with the con-
sequent release of vasoconstrictor substances that may
exacerbate vasospasm.36 These abnormalities may con-
tribute to angina during exertion or emotional stress,
two circumstances that increase myocardial work and
oxygen demand.
Because the internal thoracic artery releases more
NO than the radial artery, both basally and in response
to stimulation by acetylcholine, it is assumed that the
effects of these arginine analogues will be more promi-
nent in the internal thoracic artery. However, the
endothelium-dependent relaxation is more pronounced
in the radial artery because of the concomitant release
of both NO and non-NO, non-prostanoid hyperpolariz-
ing factor. Our observations also indicate that exoge-
nous L-arginine may compete with the NO synthase
inhibitors to restore NO synthesis and endothelium-
derived relaxation. It is widely known that L-arginine
supplementation enhances the synthesis of endotheli-
um-derived NO and restores endothelial vasodilator
function in human subjects.37,38 Consistent with this, a
recent report has shown that systemic L-arginine infu-
sions improve coronary blood flow and decrease coro-
nary vascular resistance in patients after coronary
artery bypass graft (saphenous vein) operations.39
Thus, it is possible that the beneficial effects of L-argi-
nine could be due to reversal of the action of the com-
petitive inhibition by ADMA. However, the proof that
L-arginine may overcome the decrease in epicardial
blood flow induced by high plasma levels of guanidino
compounds is still lacking.
In conclusion, the present study supports the hypoth-
esis that accumulation of methylarginines should be
considered as a risk factor for endothelial dysfunction
and abnormal vasomotor tone in arterial grafts.
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